|
1
|
McHugh JB, Visscher DW and Barnes EL:
Update on selected salivary gland neoplasms. Arch Pathol Lab Med.
133:1763–1774. 2009.PubMed/NCBI
|
|
2
|
Otsuka K, Imanishi Y, Tada Y, Kawakita D,
Kano S, Tsukahara K, Shimizu A, Ozawa H, Okami K, Sakai A, et al:
Clinical outcomes and prognostic factors for salivary duct
carcinoma: A multi-institutional analysis of 141 patients. Ann Surg
Oncol. 23:2038–2045. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Barnes L, Rao U, Krause J, Contis L,
Schwartz A and Scalamogna P: Salivary duct carcinoma. Part I. A
clinicopathologic evaluation and DNA image analysis of 13 cases
with review of the literature. Oral Surg Oral Med Oral Pathol.
78:64–73. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Johnston ML, Huang SH, Waldron JN, Atenafu
EG, Chan K, Cummings BJ, Gilbert RW, Goldstein D, Gullane PJ, Irish
JC, et al: Salivary duct carcinoma: Treatment, outcomes, and
patterns of failure. Head Neck. 38:E820–E826. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lagha A, Chraiet N, Ayadi M, Krimi S,
Allani B, Rifi H, Raies H and Mezlini A: Systemic therapy in the
management of metastatic or advanced salivary gland cancers. Oral
Oncol. 48:948–957. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Masubuchi T, Tada Y, Maruya S, Osamura Y,
Kamata SE, Miura K, Fushimi C, Takahashi H, Kawakita D, Kishimoto S
and Nagao T: Clinicopathological significance of androgen receptor,
HER2, Ki-67 and EGFR expressions in salivary duct carcinoma. Int J
Clin Oncol. 20:35–44. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cornolti G, Ungari M, Morassi ML,
Facchetti F, Rossi E, Lombardi D and Nicolai P: Amplification and
overexpression of HER2/neu gene and HER2/neu protein in salivary
duct carcinoma of the parotid gland. Arch Otolaryngol Head Neck
Surg. 133:1031–1036. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dagrada GP, Negri T, Tamborini E, Pierotti
MA and Pilotti S: Expression of HER-2/neu gene and protein in
salivary duct carcinomas of parotid gland as revealed by
fluorescence in-situ hybridization and immunohistochemistry.
Histopathology. 44:301–302. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Alotaibi AM, Alqarni MA, Alnobi A and
Tarakji B: Human epidermal growth factor receptor 2 (HER2/neu) in
salivary gland carcinomas: A review of literature. J Clin Diagn
Res. 9:ZE04–ZE08. 2015.PubMed/NCBI
|
|
10
|
Nabili V, Tan JW, Bhuta S, Sercarz JA and
Head CS: Salivary duct carcinoma: A clinical and histologic review
with implications for trastuzumab therapy. Head Neck. 29:907–912.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Skálová A, Stárek, Kucerová V, Szépe P and
Plank L: Salivary duct carcinoma-A highly aggressive salivary gland
tumor with HER-2/neu oncoprotein overexpression. Pathol Res Pract.
197:621–626. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
De Block K, Vander Poorten V, Dormaar T,
Nuyts S, Hauben E, Floris G, Deroose CM, Schöffski P and Clement
PM: Metastatic HER-2-positive salivary gland carcinoma treated with
trastuzumab and a taxane: A series of six patients. Acta Clin Belg.
71:383–388. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ghazali N, Parker L, Settle K and Lubek
JE: Sustained response of HER2-positive metastatic salivary
adenocarcinoma, not otherwise specified, treated with trastuzumab.
Oral Surg Oral Med Oral Pathol Oral Radiol. 122:292–299. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kadowaki S, Yatabe Y, Hirakawa H, Komori
A, Kondoh C, Hasegawa Y and Muro K: Complete response to
trastuzumab-based chemotherapy in a patient with human epidermal
growth factor receptor-2-positive metastatic salivary duct
carcinoma ex pleomorphic adenoma. Case Rep Oncol. 6:450–455. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Iqbal MS, Shaikh G, Chatterjee S, Cocks H
and Kovarik J: Maintenance therapy with trastuzumab in her2
positive metastatic parotid ductal adenocarcinoma. Case Rep Oncol
Med. 2014:162516342014.
|
|
16
|
Haddad R, Colevas AD, Krane JF, Cooper D,
Glisson B, Amrein PC, Weeks L, Costello R and Posner M: Herceptin
in patients with advanced or metastatic salivary gland carcinomas.
A phase II study. Oral Oncol. 39:724–727. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Limaye SA, Posner MR, Krane JF, Fonfria M,
Lorch JH, Dillon DA, Shreenivas AV, Tishler RB and Haddad RI:
Trastuzumab for the treatment of salivary duct carcinoma. Oncol.
18:294–300. 2013.
|
|
18
|
Thorpe LM, Schrock AB, Erlich RL, Miller
VA, Knost J, Le-Lindqwister N, Jujjavarapu S, Ali SM and Liu JJ:
Significant and durable clinical benefit from trastuzumab in 2
patients with HER2-amplified salivary gland cancer and a review of
the literature. Head Neck. 39:E40–E44. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Corrêa TS, Matos GDR, Segura M and Dos
Anjos CH: Second-line treatment of HER2-positive salivary gland
tumor: Ado-Trastuzumab emtansine (T-DM1) after progression on
trastuzumab. Case Rep Oncol. 11:252–257. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
van Boxtel W, Boon E, Weijs WLJ, van den
Hoogen FJA, Flucke UE and van Herpen CML: Combination of docetaxel,
trastuzumab and pertuzumab or treatment with trastuzumab-emtansine
for metastatic salivary duct carcinoma. Oral Oncol. 72:198–200.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Iguchi F, Taniguchi Z, Kusano J, Takahashi
Y and Murai N: A case of metastatic salivary duct carcinoma
successfully treated with trastuzumab-based targeted therapy. Nihon
Jibiinkoka Gakkai Kaiho. 117:1108–1114. 2014.(Japanese). View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Giltnane JM, Molinaro A, Cheng H, Robinson
A, Turbin D, Gelmon K, Huntsman D and Rimm DL: Comparison of
quantitative immunofluorescence with conventional methods for
HER2/neu testing with respect to response to trastuzumab therapy in
metastatic breast cancer. Arch Pathol Lab Med. 132:1635–1647.
2008.PubMed/NCBI
|
|
23
|
Ethier JL, Desautels D, Templeton A, Shah
PS and Amir E: Prognostic role of neutrophil-to-lymphocyte ratio in
breast cancer: A systematic review and meta-analysis. Breast Cancer
Res. 19:22017. View Article : Google Scholar : PubMed/NCBI
|
